Kyle Strickland

Overview:

Dr. Strickland specializes in cytopathology and women's and perinatal surgical pathology.  His areas of interest include epithelial and mesenchymal gynecologic neoplasia and fine needle aspiration cytology.

Positions:

Assistant Professor of Pathology

Pathology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 2005

College of Charleston

B.A. 2005

College of Charleston

MD./PhD. 2013

Medical University of South Carolina, School of Medicine

Resident, Anatomic Pathology, Harvard Medical School

Brigham and Women's Hospital

Fellow, Cytopathology, Harvard Medical School

Brigham and Women's Hospital

Fellow, Women's and Perinatal Pathology, Harvard Medical School

Brigham and Women's Hospital

Grants:

Population Health Research Support - Study of Pregnancy and Neonatal Health (SPAN) Task A

Administered By
Obstetrics and Gynecology, Maternal Fetal Medicine
Awarded By
National Institutes of Health
Role
Faculty Member
Start Date
End Date

Point-of-care cellular and molecular pathology of breast tumors on a cell phone

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Are ESR1 mutations associated with shorter progression free survival in copy number-low endometrial adenocarcinomas?

Administered By
Pathology
Awarded By
Foundation for Women's Cancer
Role
Principal Investigator
Start Date
End Date

Point-of-care cellular and molecular pathology of breast tumors on a cell phone

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

TIME Aim of the Study of Pregnancy and Neonatal Health (SPAN) Task Order A

Administered By
Obstetrics and Gynecology, Maternal Fetal Medicine
Awarded By
National Institutes of Health
Role
Faculty Member
Start Date
End Date

Publications:

Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

Authors
Kochupurakkal, BS; Parmar, K; Lazaro, J-B; Unitt, C; Zeng, Q; Reavis, H; Ganesa, C; Zhou, S; Liu, J; Palakurthi, S; Strickland, K; Howitt, B; Konstantinopoulos, P; Kirschmeier, P; Geradts, J; Drapkin, R; Matulonis, U; D'Andrea, A; Shapiro, G
MLA Citation
Kochupurakkal, Bose S., et al. “Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity.” Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, 2017. Crossref, doi:10.1158/1538-7445.am2017-2796.
URI
https://scholars.duke.edu/individual/pub1351046
Source
crossref
Published In
Clinical Research (Excluding Clinical Trials)
Published Date
DOI
10.1158/1538-7445.am2017-2796

CaMKK2-can: A dance between CaMKK2 and Rb in high-grade serous ovarian cancer patients with therapeutic potential

Authors
MLA Citation
Previs, R. A., et al. “CaMKK2-can: A dance between CaMKK2 and Rb in high-grade serous ovarian cancer patients with therapeutic potential.” Gynecologic Oncology, vol. 154, Elsevier BV, 2019, pp. 54–54. Crossref, doi:10.1016/j.ygyno.2019.04.129.
URI
https://scholars.duke.edu/individual/pub1467648
Source
crossref
Published In
Gynecologic Oncology
Volume
154
Published Date
Start Page
54
End Page
54
DOI
10.1016/j.ygyno.2019.04.129

Malignant Peritoneal Mesothelioma Arising in Young Adults With Long-standing Indwelling Intra-abdominal Shunt Catheters.

Only 50% to 70% of patients with mesothelioma report asbestos exposure. Other exposures (eg, radiation) play a role in some cases, but some patients have no obvious cause. We describe a series of patients with long-standing indwelling intra-abdominal shunt catheters who developed malignant peritoneal mesothelioma, suggesting a novel association. We identified 7 patients who had shunts and subsequently developed mesothelioma (5 women; median age: 31 y, range: 18 to 45 y). Clinical history and pathology materials were reviewed, and RNA sequencing was performed. Clinical presentations varied; 6 patients had hydrocephalus and a ventriculoperitoneal shunt, and 1 patient had portal hypertension and a portoatrial shunt. The median duration of shunt therapy in 5 cases was 29 years (range: 12 to 35 y); the remaining 2 patients also had shunts for many years, but specific details were unavailable. Two patients had radiotherapy for malignancies in childhood. One had an alleged exposure to asbestos and 1 had prior exposure to talc. The rest had no known risk factors. Histologically, all tumors were purely epithelioid. Treatments included surgical debulking, chemotherapy, and palliative care. All 7 died of disease (median survival: 7 mo, range: 1 to 18 mo). Molecular testing showed loss of NF2 and CDKN2A/B and a BAP1 mutation in 1 case, and no genomic alterations associated with mesothelioma in 2 cases. Peritoneal mesothelioma may represent a complication of long-standing indwelling shunt catheters. The mechanism is unknown, but chronic peritoneal irritation may play a role. Albeit rare, mesothelioma should be considered in patients with a shunt who present with new ascites.
Authors
Mujahed, T; Tazelaar, HD; Sukov, WR; Halling, KC; Davila, JI; Glass, C; Pavlisko, EN; Strickland, KC; Roggli, V; Haque, M; Mneimneh, W; Carter, E; Galateau-Salle, F; Glidden, D; Garcia-Kennedy, R; Larsen, BT
MLA Citation
Mujahed, Tala, et al. “Malignant Peritoneal Mesothelioma Arising in Young Adults With Long-standing Indwelling Intra-abdominal Shunt Catheters.Am J Surg Pathol, vol. 45, no. 2, Feb. 2021, pp. 255–62. Pubmed, doi:10.1097/PAS.0000000000001574.
URI
https://scholars.duke.edu/individual/pub1456530
PMID
32826527
Source
pubmed
Published In
American Journal of Surgical Pathology
Volume
45
Published Date
Start Page
255
End Page
262
DOI
10.1097/PAS.0000000000001574

Thrombus on the Inflow Cannula of the HeartWare HVAD: An Update. Platform presentation.

Authors
Glass, C; Strickland, K; Watkins, J; Padera, R
MLA Citation
URI
https://scholars.duke.edu/individual/pub1356299
Source
manual
Published Date

Results and clinical utilization of next-generation tumor sequencing in gynecologic oncology patients

Authors
Watson, CH; Spinosa, D; Wong, J; Strickland, KC; Berchuck, A; Previs, RA
MLA Citation
Watson, C. H., et al. “Results and clinical utilization of next-generation tumor sequencing in gynecologic oncology patients.” Gynecologic Oncology, vol. 159, Elsevier BV, 2020, pp. 290–91. Crossref, doi:10.1016/j.ygyno.2020.05.511.
URI
https://scholars.duke.edu/individual/pub1467649
Source
crossref
Published In
Gynecologic Oncology
Volume
159
Published Date
Start Page
290
End Page
291
DOI
10.1016/j.ygyno.2020.05.511